MINTZ LEVIN
Mintz Levin Cohn Ferris Glovsky and Popeo PC

STATE BIOSIMILAR SUBSTITUTION LAWS

***Please note*: This chart is for informational purposes only and does not constitute legal advice or opinions regarding any specific facts relating to the substitution of biosimilars. You should seek the advice of experienced legal counsel when reviewing options and obligations in complying with biosimilar substitution laws.**

State laws and regulations concerning drug policy change quickly. This chart is current as of August 30, 2016.

States have generally used federal standards to define "interchangeable" or "interchangeability," as set forth in 42 U.S.C. § 262(k)(4). Interchangeable or Interchangeability means (1) the biological product is biosimilar to the reference product and can be expected to produce the same clinical result as the reference product in any given patient; and (2) if administered more than once, the risk in terms of safety or diminished efficacy of alternating between the use of the biological product and reference product is not greater than the risk of using the reference product alone.

This chart provides **general information and not legal advice** regarding any specific facts or circumstances. For more information about state biosimilar substitution laws, or other pharmaceutical matters, please contact the Mintz Levin attorney with whom you work, or any of the following attorneys:
Theresa Carnegie (TCCarnegie@mintz.com | 202.661.8710);
Ellyn Sternfield (ELSternfield@mintz.com | 202.434.7445);
Joanne Hawana (JSHawana@mintz.com | 202.434.7349);
Sarah Beth Kuyers (SSKuyers@mintz.com | 202.434.7453).

1) Arizona	8) Idaho	15) New Jersey	22) Tennessee
2) California	9) Illinois	16) North Carolina	23) Texas
3) Colorado	10) Indiana	17) North Dakota	24) Utah
4) Delaware	11) Kentucky	18) Oregon	25) Virginia
5) Florida	12) Louisiana	19) Pennsylvania	26) Washington
6) Georgia	13) Massachusetts	20) Puerto Rico	
7) Hawaii	14) Missouri	21) Rhode Island	

State	Substitution Requirements	Pharmacy Notification Requirements (to prescriber, patient, or others)	Recordkeeping Requirements
Arizona H.B. 2310 Effective December 31, 2016	A pharmacist may substitute a biosimilar for a prescribed biologic only if: 1. FDA has determined the biologic is interchangeable with the prescribed biologic; and 2. The prescriber has not designated in writing or electronically that substitution is prohibited.	The patient must be notified of the substitution. The pharmacist (or designee) must notify the prescriber: 1. Of the drug's name and manufacturer; 2. Within 5 days of dispensing the biologic; and 3. Via an electronic means (i.e., medical records system, prescribing technology, pharmacy record) (with exceptions).	The pharmacy must keep a written or electronic record of the dispensed biologic for at least 7 years after the substitution.
California S.B. 671 Effective January 1, 2016	A pharmacist may substitute an alternative biological product for a prescribed biologic if 1. The alternative is interchangeable; 2. The prescriber did not indicate "do not substitute"; and 3. The cost to the patient of the alternative is the same as or less than the price of the prescribed biologic.	The patient must be notified of the substitution. The pharmacist (or designee) must notify the prescriber: 4. Of the drug's name and manufacturer; 5. Within 5 days of dispensing the biologic; and 6. Via an interoperable electronic medical records system (with exceptions).	None.
Colorado S.B. 15-071 Effective April 3, 2015 (date signed by Governor)	A pharmacist may substitute a biosimilar for a prescribed biologic only if: 1. FDA has determined the biologic is interchangeable with the prescribed biologic; 2. The prescriber has not expressed a preference against substitution; and 3. The prescribed biologic costs more than the biosimilar.	The pharmacist must notify the "purchaser" of the substitution in writing or orally. The pharmacist (or designee) must notify the prescriber: 1. Of the drug's name and manufacturer; 2. Within a reasonable amount of time after dispensing the biologic; and 3. Via an interoperable electronic medical records system (with exceptions).	The pharmacy must keep a written or electronic record of the dispensed biologic for at least 2 years after the substitution.

State	Substitution Requirements	Pharmacy Notification Requirements (to prescriber, patient, or others)	Recordkeeping Requirements
Delaware S.B. 118 Effective May 28, 2014 (date signed by Governor)	A pharmacist may substitute a biosimilar for a prescribed biologic if: 1. FDA has determined the biologic is interchangeable with the prescribed biologic; and 2. The prescriber has not expressed a preference against substitution.	The pharmacist (or designee) must notify the patient in writing that FDA approved the dispensed biosimilar as interchangeable with the prescribed biologic. The pharmacist (or designee) must notify the prescriber of the substitution: 1. Within 48 hours of dispensing; and 2. Via writing, fax, telephone, or electronic means.	The pharmacist must record on the prescription label and in the dispensation record: 1. The name of the dispensed biosimilar followed by "substituted for" and the name of the prescribed biologic; and 2. The manufacturer of the dispensed biosimilar Records of the substitution must be kept for at least 3 years after dispensing.
Florida H.B. 365 Effective July 1, 2013	A pharmacist may substitute a biosimilar for a prescribed biologic if: 1. FDA has determined the biologic is interchangeable with the prescribed biologic; and 2. The prescriber has not expressed a preference against substitution.	The pharmacist must notify the person presenting the prescription of the substitution, along with the amount of the retail price difference between the prescribed biologic and the substituted biosimilar, and the person must be informed of the right to refuse such substitution.	The pharmacist must keep written or electronic records of the substitution for at least 2 years.
Georgia S.B. 51 Effective July 1, 2015	A pharmacist may substitute a biosimilar for a prescribed biologic if: 1. FDA has determined the biologic is interchangeable with the prescribed biologic; 2. Neither the prescriber nor the patient has expressed preference against substitution; and 3. The substituted biosimilar has the lowest retail price of all interchangeable biologics in stock (when a prescriber prescribes a biologic by its nonproprietary name).	The pharmacist (or designee) must notify the prescriber: 1. Of the drug's name and manufacturer; 2. Within 48 hours (excluding weekends and holidays) after dispensing the biologic; and 3. Via an electronic means (i.e., medical records system, prescribing technology, pharmacy record) (with exceptions).	The name and an explanation of the substituted biologic must be on the prescription label (with exceptions). The pharmacist also must record on the original prescription that the substitution was made and the name of the dispensed biologic.

State	Substitution Requirements	Pharmacy Notification Requirements (to prescriber, patient, or others)	Recordkeeping Requirements
Hawaii H.B. 254 Effective July 1, 2016	A pharmacist must substitute an interchangeable biosimilar for a prescribed biologic if: 1. The prescriber does not prohibit substitution; 2. The prescriber and patient consent to the substitution; and 3. The substitution results in a financial savings to the consumer or ultimate payer (including third party payers).	The pharmacist must inform the "consumer" of the financial savings from the substitution, the right to refuse the substitution, and the differences between the prescribed brand name biologic and the interchangeable biosimilar when filling any prescription order for a brand name biologic. The pharmacist (or designee) must notify the prescriber: 1. Of the drug's name and manufacturer; 2. Within 24 hours (excluding weekends and holidays) after dispensing the biologic; and 3. Via an electronic means (i.e., medical records system, prescribing technology, pharmacy record) (with exceptions).	The prescription label for interchangeable biosimilars must contain the statement "interchangeable with [brand name of biologic prescribed or reference product]." The pharmacist must keep written or electronic records of the substitution for at least 5 years.
Idaho 27.01.01 - Rule of the Idaho Board of Pharmacy Effective April 11, 2015 (after close of 2015 regular legislative session)	A pharmacist may substitute a biosimilar for a prescribed biologic if: 1. FDA has determined the biosimilar is interchangeable with the prescribed biologic and it has been published in the *Purple Book*; 2. The prescriber does not indicate that the prescribed biologic must be dispensed; and 3. The name of the drug and manufacturer or NDC number is documented in the patient's medical record.	N/A	The name of the drug and manufacturer or NDC number must be documented in the patient's medical record if a pharmacist substitutes a biologic.

State	Substitution Requirements	Pharmacy Notification Requirements (to prescriber, patient, or others)	Recordkeeping Requirements
Illinois S.B. 455 Effective January 1, 2016	A pharmacist may substitute a biosimilar for a prescribed biologic only if: 1. FDA has determined the substitute is interchangeable with the prescribed biologic; and 2. The prescriber has not indicated that the biologic may not be substituted.	The pharmacist must inform the patient of the substitution. The pharmacist also must notify the prescriber: 1. Of the name and manufacture of the dispensed biologic; 2. Within 5 business days of dispensing; and 3. Via an interoperable EHR system (with exceptions).	The pharmacy must keep a record of the dispensed biologic for at least 5 years.
Indiana S.B. 262 Effective July 1, 2014	A pharmacist may substitute a biosimilar for a prescribed biologic if: 1. FDA has determined the substitute is interchangeable with the prescribed biologic; and 2. The prescriber has indicated that the biologic may be substituted.	The pharmacist must inform the "customer" of the substitution. The pharmacist also must notify the prescriber: 1. Of the name and manufacture of the dispensed biologic; 2. Within 10 calendar days of dispensing; and 3. Via an interoperable EHR system (with exceptions).	The pharmacy must keep a record of the dispensed biologic, whether in written or electronic format, for at least 2 years. In addition, the prescriber must keep a record of the dispensed biologic, whether the patient's original health records or microfilms, for at least 7 years.
Kentucky S.B. 134 Effective October 1, 2016	A pharmacist must substitute a lower priced interchangeable biological product when a brand name biological product not listed in the Board of Pharmacy's nonequivalent drug product formulary is prescribed, unless otherwise instructed by the patient or prescriber.	The pharmacist must notify the prescriber: 1. Of the name and manufacture of the dispensed biologic; 2. Within 5 calendar days of dispensing; and 3. Via an interoperable EHR system (with exceptions).	The pharmacy must keep a record of the dispensed biologic for at least 2 years.

State	Substitution Requirements	Pharmacy Notification Requirements (to prescriber, patient, or others)	Recordkeeping Requirements
Louisiana H.B.319 Effective August 1, 2015	A pharmacist may substitute a biosimilar for a prescribed biologic if: 1. FDA has determined the substitute is interchangeable with the prescribed biologic; 2. The prescriber has not indicated that substitution is prohibited; and 3. The patient has consented to the substitution.	The pharmacist (or designee) must notify the prescriber: 1. Of a dispensed biological product's name and manufacturer; 2. Within 5 days of dispensation; and 3. Via any means.	No recordkeeping requirements that are specific to biological products (general pharmacy recordkeeping rules apply).
Massachusetts H.3734 Effective September 21, 2014 (90 days after date signed by Governor)	A pharmacist may substitute a biosimilar for a prescribed biologic (even when prescribed by brand name) if: 1. FDA has determined it is interchangeable with the prescribed biologic; and 2. The prescriber has not instructed in writing that substitution is not authorized.	The pharmacist (or designee) must notify the patient (or the patient's authorized representative) in writing of the substitution. The pharmacist (or designee) must notify the prescriber of the substitution: 1. Within a reasonable amount of time after the substitution is made; and 2. Via the patient's interoperable electronic health record (with exceptions).	The pharmacist (or designee) must keep a record of each substitution for at least 1 year since the last record of dispensation. In addition, the prescriber and the administering practitioner must keep a record of each substitution for at least 1 year since the dispensation of an interchangeable biologic.
Missouri S.B. 875 Effective August 28, 2016	A pharmacist may substitute a biosimilar for a prescribed biologic (even when prescribed by brand name) if: 1. FDA has determined it is interchangeable with the prescribed biologic; 2. The biosimilar is less expensive than the prescribed biologic; and 3. The prescriber has indicated that a substitution is permitted.	The pharmacy must inform the patient of the substitution. The pharmacist (or designee) must notify the prescriber of the substitution: 1. Of a dispensed biological product's name and manufacturer; 2. Within 5 days after dispensing; and 3. Via an electronic means (i.e., medical records system, prescribing technology, pharmacy record) (with exceptions).	The name of the manufacturer for the substituted biosimilar must appear on the label or the pharmacist's records.

State	Substitution Requirements	Pharmacy Notification Requirements (to prescriber, patient, or others)	Recordkeeping Requirements
New Jersey A2477 Effective January 1, 2016	A pharmacist may substitute an alternative biological product if: 1. The prescriber did not indicate "do not substitute; and 2. The alternative is interchangeable or designated by FDA as therapeutically equivalent.	The pharmacist (or designee) must notify the prescriber: 1. Of a dispensed biological product's name and manufacturer; 2. Within 5 business days of dispensation; and 3. Via electronic means or fax.	None.
North Carolina H.B. 195 Effective October 1, 2015	A pharmacist may substitute a biosimilar for a prescribed biologic if: 1. FDA has determined it is interchangeable with the prescribed biologic; 2. The prescriber has not instructed that substitution is not authorized; 3. The manufacturer's name and distributor's name (if different than the manufacturer's name) appear on the label of the stock package; 4. It is manufactured according to Good Manufacturing Practices; 5. On solid oral dosage forms, the manufacturer or distributor is identified by logo, identification mark, or product name; and 6. The manufacturer has adequate provisions for drug recall and for the return of outdated drugs.	The pharmacist (or designee) must notify the prescriber: 1. Of the product's name and manufacturer; 2. Within a reasonable amount of time after dispensing the biologic; and 3. Via an electronic means (i.e., medical records system, prescribing technology, pharmacy record) (with exceptions)	For prescriptions ordered orally by a prescriber, the pharmacist must note the prescriber's instructions about dispensation on the file copy of the prescription.

State	Substitution Requirements	Pharmacy Notification Requirements (to prescriber, patient, or others)	Recordkeeping Requirements
North Dakota S.B. 2190 Effective August 1, 2013	A pharmacy may substitute a biosimilar for a prescribed biologic only if: 1. FDA has determined it is interchangeable with the prescribed biologic; and 2. The prescriber has not indicated that the brand name biologic is medically necessary.	The pharmacy must inform the individual receiving the biologic that the biologic may be substituted with a biosimilar and that he/she has a right to refuse the biosimilar. Within 24 hours, the pharmacy also must notify the prescriber of the substitution orally, in writing, or via electronic transmission.	The pharmacy must keep a record of the substitution for at least 5 years. In addition, the prescriber must keep a record of the substitution for at least 5 years.
Oregon S.B. 460 Effective June 6, 2013; amendments effective January 1, 2016	A pharmacy or pharmacist may substitute a biosimilar for the prescribed biologic only if: 1. FDA has determined the biosimilar is interchangeable with the prescribed biologic; and 2. The prescriber has not indicated on the prescription that substitution is prohibited.	The pharmacy or pharmacist must inform the patient of the substitution prior to dispensing. Currently, the law requires the pharmacy or pharmacist to notify the prescriber of the substitution within 3 business days after the dispensing date. However, this requirement will be deleted via amendments to the law effective January 1, 2016.	The pharmacy or pharmacist must keep a record of the substitution for at least 3 years.
Pennsylvania S.B. 514 Effective September 18, 2016	A pharmacy or pharmacist may substitute a biosimilar for the prescribed biologic only if: 1. FDA has determined the biosimilar is interchangeable with the prescribed biologic; and 2. The prescriber has not indicated verbally or in writing that substitution is prohibited.	The person presenting the prescription must be notified of the substitution. The pharmacist (or designee) must notify the prescriber: 1. Of the product's name and manufacturer; 2. Within 72 hours after dispensing the biologic; and 3. Via an electronic means (i.e., medical records system, prescribing technology, pharmacy record) (with exceptions).	The pharmacist must keep a record of the substitution.

State	Substitution Requirements	Pharmacy Notification Requirements (to prescriber, patient, or others)	Recordkeeping Requirements
Puerto Rico 141-2015 Effective September 8, 2015	A pharmacist may substitute a biological product only if: 1. The biological product has been approved as interchangeable with the prescribed product per 42 U.S.C. § 262(k)(4) and is included in the Purple Book; or 2. The FDA has designated the biological product as therapeutically equivalent with the prescribed product according to the most recent edition of the Orange Book.	The pharmacist should inform the patient of the substitution prior to dispensing and that the patient may refuse the substitution. Within 2 days, the pharmacist (or designee) must inform prescriber of the substitution, including the name and manufacturer of the dispensed biological product, via telephone, fax, email, or other prevailing means.	The pharmacy should keep a record of the notification to the prescriber for 3 years.
Rhode Island H.B. 7816 Effective June 28, 2016	A pharmacist shall substitute a biological product with an interchangeable biologic unless: 1. The individual presenting the prescription requests otherwise; or 2. The prescribers order the pharmacist to dispense as brand name necessary (either in writing or orally).	The pharmacist must inform the patient of the substitution. The pharmacist (or designee) must also notify the prescriber: 1. Of the product's name and manufacturer; 2. Within 5 business days after dispensing a biologic; and 3. Via an electronic means (i.e., medical records system, prescribing technology, pharmacy record) (with exceptions).	The pharmacist must indicate the dispensed product on the prescription order.

State	Substitution Requirements	Pharmacy Notification Requirements (to prescriber, patient, or others)	Recordkeeping Requirements
Tennessee S.B. 984 Effective May 4, 2015	Prescribers must allow pharmacists to make substitutions with interchangeable biosimilars, unless an exception applies. Available exceptions include situations in which the prescriber determines that a prescribed biologic is medically necessary.	The pharmacist must notify the patient of the substitution by noting the substitution on the prescription label. The pharmacist (or designee) must also notify the prescriber: 4. Of the product's name and manufacturer; 5. Within a reasonable amount of time after the substitution is made; and 6. Via an electronic means (i.e., medical records system, prescribing technology, pharmacy record) (with exceptions).	The pharmacist must maintain a record of any dispensed biologic for 2 years.
Texas H.B. 751 Effective September 1, 2015	A pharmacist may substitute a biosimilar for the prescribed biologic only if: 1. FDA has determined it is interchangeable with the prescribed biologic; 2. The prescriber has not certified on the prescription that the prescribed brand is medically necessary; 3. The patient has not indicated a choice for the band name biologic; and 4. The interchangeable biologic costs less than the prescribed biologic.	The pharmacist must notify the patient personally or through an agent or employee: 1. Prior to dispensing the biologic; 2. That a less expensive interchangeable biologic is available; and 3. The patient must be given the opportunity to choose between the biosimilar or prescribed biologic. The pharmacist also must notify the prescriber: 1. Of the product's name and manufacturer; 2. Within 3 days after dispensing the biologic; 3. Via an electronic means (i.e., medical records system, prescribing technology, pharmacy record) (with exceptions). The requirement to notify the prescriber expires on September 1, 2019.	The pharmacist must put on the container "substituted for brand prescribed" or "substituted for [brand/biologic name]." Pharmacists must keep a record on the prescription form of the dispensed biologic's name, strength, and manufacturer or distributor. Additional requirements for container labels apply to Class A and Class E pharmacies.

State	Substitution Requirements	Pharmacy Notification Requirements (to prescriber, patient, or others)	Recordkeeping Requirements
Utah H.B.279 Effective May 12, 2015	A pharmacist may substitute a biosimilar for the prescribed biologic only if: 1. FDA has determined it is interchangeable with the prescribed biologic and it is "permitted to move in interstate commerce"; 2. The purchaser specifically requests or consents to the substitution; 3. The pharmacist or pharmacy intern counsels the patient on the use and expected response to the biologic, whether a substitute or not; and 4. The prescriber has not prohibited substitution.	The pharmacist or pharmacy intern must notify the "purchaser" of a substitution. Out-of-state mail order pharmacies must notify the patient by telephone or in writing. The pharmacist (or designee) also must notify the prescriber: 1. Of the product's name and manufacturer; 2. Within 5 business days of dispensing the biologic; 3. Via electronic health records (with exceptions). An entry in an electronic system is presumed to provide notice to the prescriber, otherwise notification can be done through other means.	If the prescriber orders the prescription orally, the pharmacist or pharmacy intern must make a note of the prescriber's directions about substitution, as well as the prescriber's name, the words "orally by," and the initials of the pharmacist or pharmacy intern. The dispensed biosimilar's container must be labeled with the name of the product. The pharmacist, pharmacy intern, or pharmacy technician must indicate on the prescription's file copy the prescribed biologic and the dispensed biosimilar's names.
Virginia S.B. 1285/ H.B. 1422 Effective July 1, 2013	A pharmacist may dispense a biosimilar that the FDA has licensed as interchangeable with the prescribed biologic, unless: 1. The prescriber indicates the substitution is not authorized by specifying on prescription "brand medically necessary"; or 2. The patient insists that the prescribed product be dispensed.	The pharmacist must notify the patient prior to dispensing a substituted biosimilar. In addition, the patient must be provided the retail cost information for both the prescribed biologic and the dispensed biosimilar at the time of substitution. This second patient-notification requirement expired on July 1, 2015. The pharmacist (or designee) also must notify the prescriber of the substitution: 1. Within 5 business days of dispensing; and 2. Via writing, telephone, or electronic means. (NOTE: This provision expired on July 1, 2015.)	Records of substitutions must be kept for at least 2 years from the date of dispensing. For substitutions, the pharmacist (or designee) must indicate on the dispensation record and prescription label the name of manufacturer or distributor of the dispensed biosimilar. The pharmacist (or designee) also must label the drug with the name of the biosimilar followed by the words "substituted for [name of prescribed biologic]."

State	Substitution Requirements	Pharmacy Notification Requirements (to prescriber, patient, or others)	Recordkeeping Requirements
Washington S.B. 5935 Effective July 24, 2015	A pharmacist must dispense an interchangeable biosimilar if: 1. It is in stock; 2. It has a lower wholesale price than the prescribed biologic cheaper and in stock; 3. The prescriber did not specify in the prescription that substitution is prohibited; and 4. The patient or patient's representative does not ask for the prescribed biologic. Every prescription must contain an instruction as to whether or not an interchangeable biosimilar may be substituted in its place (with exceptions).	Every pharmacy must post a sign that is visible to patients regarding potential substitution of a less expensive biosimilar. The pharmacist (or designee) must notify the prescriber: 1. Of the product's name and manufacturer or NDC number; 2. Within 5 business days of dispensing the biologic; 3. Via an electronic medical record and by another means if the prescriber cannot access the record. An entry in an electronic system is presumed to provide notice to the prescriber.	For oral prescriptions, the pharmacist must record the prescriber's directions about substitution in the file copy of the prescription. The pharmacist must note the manufacturer of the dispensed drug on the file copy of a prescription, which must be maintained for 2 years.